| Literature DB >> 30068367 |
Joana Figueiredo1,2, Soraia Melo1,2,3, Kimberley Gamet4, Tanis Godwin5, Susana Seixas1,2, João M Sanches6, Parry Guilford5, Raquel Seruca7,8,9.
Abstract
The aim of this study was to uncover the pathogenic relevance and the underlying molecular mechanism of a novel CDH1 variant found in a Hereditary Diffuse Gastric Cancer family (p.L13_L15del), which affects the signal peptide of E-cadherin without changing the remaining predicted sequence. We verified that p.L13_L15del cells yield low levels of E-cadherin, decreased cell adhesion and enhanced cell invasion. Further, we demonstrated that the disruption of the highly conserved hydrophobic core of the signal peptide hampers the binding of cellular components crucial for E-cadherin translation and translocation into the endoplasmic reticulum, constituting a new molecular basis for the loss of a tumour suppressor gene causative of hereditary cancer.Entities:
Keywords: CDH1; E-cadherin; Germline variants; Hereditary Diffuse Gastric Cancer; Post-translational mechanism; Signal peptide
Mesh:
Substances:
Year: 2018 PMID: 30068367 PMCID: PMC6090902 DOI: 10.1186/s12943-018-0859-0
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 27.401
Fig. 1Description and functional characterization of p.L13_L15del variant. a The pedigree of a New Zealand family carrying the p.L13_L15del mutation is represented. Symbols with a slash indicate deceased individuals. The proband is identified with the arrowhead. Cancer or other known diseases affecting family members were indicated. The actual age or the age at the time of death is displayed below each individual. TAR denotes thrombocytopenia-absent radius syndrome and MMR stands for mismatch repair. b Schematic representation of E-cadherin comprising the signal peptide, precursor, extracellular, transmembrane and cytoplasmic domains. Multiple sequence alignment of five signal peptide sequences is shown (hEcad, human E-cadherin; chEcad, chimpanzee E-cadherin; mEcad, mouse E-cadherin; xEcad, Xenopus E-cadherin; hPcad, human P-cadherin). Conserved residues are highlighted in black boxes, and residues conserved in at least four cadherins are shown in dark grey. c Total levels of E-cadherin were analyzed by Western Blot in CHO cells transfected with vectors encoding the E-cadherin mutant p.L13_L15del, the wild-type protein, and the empty vector (Mock). α-Tubulin was used as a loading control. Band intensity was quantified and normalized against wild-type cells. Intensity average + SE is represented in the graph. d Immunofluorescence was applied to evaluate protein localization. E-cadherin is shown in green and nuclei were counterstained with DAPI (blue). e Expression profiles of mutant (red) and wild-type cells (blue) were quantified. Average intensity in each internuclear position + SE is represented in the graph. Mean and SE of fluorescence intensity at the plasma membrane (internuclear position 50) is presented. f Invasive ability mean of wild-type and p.L13_L15del mutant cells. g Average area + SE of aggregates. h Cell-cell aggregation phenotypes of the different cell lines. Representative outlines of wild-type and mutant cellular aggregates are presented on the bottom. ** represents p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001
Fig. 2p.L13_L15del variant does not affect E-cadherin trafficking or degradation. a CDH1 and 18S mRNA levels were analyzed by real-time PCR in CHO cells transfected with vectors encoding the E-cadherin mutant L13_L15del, the wild-type protein, and the empty vector (Mock condition). 18S was used as endogenous control. b Total levels of E-cadherin were analyzed in Mock, wild-type and L13_L15del mutant cells upon treatment with 2% DMSO and 10 μM MG132. α-Tubulin was used as a loading control. c Band intensity average + SE is presented. d Flow cytometry was used to assess surface E-cadherin in cells untreated and treated with DMSO or with the proteasome inhibitor MG132. e Graph representing the percentage of cells positive for E-cadherin. f For each sample, median fluorescence intensity + SE was determined and normalized for untreated wild-type cells. * represents p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. g Scheme illustrating the interaction of a chemical chaperone with a newly synthesized polypeptide at the lumen of the endoplasmic reticulum. The chemical chaperone assists the folding of the protein and evades its quality control and degradation. At the cytoplasm, MG132 blocks the proteolytic activity of the 26S proteasome complex, resulting in accumulation of immature and unfolded proteins
Fig. 3The p.L13_L15del E-cadherin mutant is regulated by cellular post-translational mechanisms. a cDNA sequences of mutant plasmids inducing the deletion of one, two or three leucine residues. b Representative scheme of the cell-free system for in vitro protein translation. Constructs encoding the wild-type and the mutant CDH1 cDNAs were used as templates for the production of E-cadherin molecules. c Coupled transcription and translation of E-cadherin was detected by Western blotting. d Band intensity was quantified and normalized against wild-type plasmid. Intensity average + SE is represented in the graph. e Illustration of the cellular model: E-cadherin negative cells were transfected with plasmids encoding the wild-type and the sequential CDH1 mutants. f E-cadherin levels produced by cells transfected with the p.L15del, the p.L14_L15del and the p.L13_L15del mutants. α-Tubulin was used as a loading control. g Quantification of band intensity is showed in the graph. (h) Regulation mechanism of E-cadherin mutant p.L13_L15del. In a wild-type context, the binding of signal recognition particle (SRP) to the signal peptide sequence of the nascent polypeptide causes a temporary pause in translation. Subsequently, SRP-bound ribosome attaches to SRP receptor located at the membrane of the endoplasmic reticulum, enabling translation to continue and translocation to begin. SRP is released and SRP receptor is recycled. The newly synthesized protein undergoes folding and trafficking to its correct location at the plasma membrane. The presence of the p.L13_L15del mutation can, however, impair the binding of SRP and, consequently, induce an evident arrest of E-cadherin translation, which is associated with several deleterious cellular effects